Scott Berry

7.8k total citations · 2 hit papers
72 papers, 3.2k citations indexed

About

Scott Berry is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Scott Berry has authored 72 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 18 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Scott Berry's work include Colorectal Cancer Treatments and Studies (36 papers), Cancer Treatment and Pharmacology (20 papers) and Economic and Financial Impacts of Cancer (13 papers). Scott Berry is often cited by papers focused on Colorectal Cancer Treatments and Studies (36 papers), Cancer Treatment and Pharmacology (20 papers) and Economic and Financial Impacts of Cancer (13 papers). Scott Berry collaborates with scholars based in Canada, United States and Spain. Scott Berry's co-authors include Malcolm J. Moore, Derek J. Jonker, Niall C. Tebbutt, Guy van Hazel, John Zalcberg, Marianne Krahn, Dongsheng Tu, Timothy Price, Christos S. Karapetis and Chris J. O’Callaghan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Scott Berry

71 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab for the Treatment of Colorectal Cancer

2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. New England Journal of Medicine profile →
American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer

2011 388 citations Scott Berry et al. profile →

Peers

Countries citing papers authored by Scott Berry

Since Specialization

Citations

This map shows the geographic impact of Scott Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Berry more than expected).

Fields of papers citing papers by Scott Berry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Berry. The network helps show where Scott Berry may publish in the future.

Co-authorship network of co-authors of Scott Berry

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Berry. A scholar is included among the top collaborators of Scott Berry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Berry. Scott Berry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28–29, October 2022	Current Oncology	Sharlene Gill, Shahid Ahmed et al.	1
2	Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income Country With Free Universal Public Healthcare	The Oncologist	Sanjeeva Gunasekera, Christopher M. Booth et al.	6
3	Breaking Down Barriers to Detection and Care in Early-Age-Onset Colorectal Cancer in Canada	Current Oncology	Michael J. Raphael, Mary A. De Vera et al.	3
4	Competency-Based Workforce Development and Education in Global Oncology	Current Oncology	Nazik Hammad, Ntokozo Ndlovu et al.	1
5	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023	Current Oncology	Maxime Chénard-Poirier, Ravi Ramjeesingh et al.	0
6	First-line Palliative Chemotherapy for Colorectal Cancer: a Population-based Analysis of Delivery and Outcomes in a Single-payer Health System	Clinical Oncology	Brooke E. Wilson, Christopher M. Booth et al.	1
7	Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry	JCO Global Oncology	Don Thiwanka Wijeratne, Christopher M. Booth et al.	2
8	Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry	JCO Global Oncology	Matthew Jalink, Fábio Ynoe de Moraes et al.	10
9	Training of oncologists: results of a global survey	ecancermedicalscience	Fidel Rubagumya, Wilma M. Hopman et al.	7
10	Value assessment of oncology drugs using a weighted criterion‐based approach	Cancer	Doreen A. Ezeife, François Dionne et al.	10
11	Open-Label Phase 2 Clinical Trial of ManNAc for GNE Myopathy (S23.008)	Neurology	Nuria Carrillo, Marjan Huizing et al.	1
12	The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement	Current Oncology	Ana Beatriz Kinupe Abrahão, Safiya Karim et al.	7
13	A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis	Clinical Colorectal Cancer	Ana Beatriz Kinupe Abrahão, Yoo‐Joung Ko et al.	61
14	Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone	Canadian Urological Association Journal	Fred Saad, Eric Winquist et al.	9
15	Developing Canadian oncology education goals and objectives for medical students: a national modified Delphi study	CMAJ Open	Vincent C. Tam, Paris‐Ann Ingledew et al.	6
16	Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes	Cancer Treatment Reviews	Sharlene Gill, Scot Dowden et al.	13
17	The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?	Expert Review of Pharmacoeconomics & Outcomes Research	Kelly Lien, Scott Berry et al.	5
18	Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study	Annals of Oncology	Eric Van Cutsem, Fernando Rivera et al.	423
19	A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining	Investigational New Drugs	Rafal Wierzbicki, Derek J. Jonker et al.	26
20	Cetuximab for the Treatment of Colorectal Cancer breakdown →	New England Journal of Medicine	Derek J. Jonker, Chris J. O’Callaghan et al.	1413

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact